Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors

…, G Juliá-Serdá, F León-Marrero… - The Journal of …, 2016 - jrheum.org
Objective. Pulmonary arterial hypertension (PAH) prevalence has been reported to be
between 0.5% and 17% in systemic lupus erythematosus (SLE). This study assessed PAH …

Effect of a pulmonary embolism diagnostic strategy on clinical outcomes in patients hospitalized for COPD exacerbation: a randomized clinical trial

…, D Aisa, B González-Quero, L Chasco, F León-Marrero… - Jama, 2021 - jamanetwork.com
Importance Active search for pulmonary embolism (PE) may improve outcomes in patients
hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD). Objective To …

[HTML][HTML] Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol

…, S Cadenas Menéndez, F León Marrero… - Frontiers in Public …, 2022 - frontiersin.org
Introduction Pulmonary arterial hypertension (PAH) is a rare, multifactorial, chronic
condition that requires ongoing monitoring and assessment. PAHcare™ is a novel, patient-centered …

[HTML][HTML] Assessing the clinical benefit, safety, and patient-reported outcomes with the use of the PAHcare™ digital platform in pulmonary arterial hypertension: a pilot …

GP Peñate, NO Parra, JAD Morera… - Frontiers in Public …, 2024 - frontiersin.org
Introduction Digital health interventions, particularly mobile health platforms, have shown
promise in supporting patients with respiratory conditions, but their application in pulmonary …

Safety of inhaled nitric oxide withdrawal in severe chronic pulmonary hypertension

…, D Alemán‐Segura, F LeónMarrero… - Pulmonary …, 2024 - Wiley Online Library
Inhaled nitric oxide (iNO) is a potent and selective pulmonary vasodilator with a safety concern
due to rebound pulmonary hypertension (PH) associated with its withdrawal. We report …

Effect of CPAP on long-term mortality in overlap syndrome: is hypercapnic the best appropriate determinant?

AM Esquinas, FL Marrero, JN Esteva - Lung, 2014 - Springer
Overlap syndrome and represents a complex clinical condition in pulmonary medicine. We
discuss in this letter factors related with mortality after long-term effects CPAP and key …

Differences in COPD: Smokers versus non smokers

CC Lopez, CC Macario, FL Marrero, GJ Serdá… - 2015 - Eur Respiratory Soc
Introduction: in all epidemiological studies there are always a proportion of never smoking
COPD patients. This study aims to characterize the difference between smokers and never …

Melanoma. Guía clínica práctica

…, R Lara-Peñaranda, F de-León-Marrero… - 2023 - sms.carm.es
Si en 2020 se produjeron 324.635 nuevos casos de melanoma cutáneo en el mundo, 5.728
fueron diagnosticados en nuestro país. En la Región de Murcia se diagnosticaron entre …

Fase final de la validación transcultural al español de la escala Hair Specific Skindex-29: sensibilidad al cambio y correlación con la escala SF-12

…, JMV Miralles, FJA Gallego, FJ de León Marrero… - Actas Dermo …, 2019 - Elsevier
Antecedentes y objetivo Previamente se había iniciado el proceso metodológico para la
validación transcultural al idioma español de la escala Hair Specific Skindex-29 (HSS-29), que …

[CITATION][C] Vanishing lung syndrome: fifteen years after bullectomy

J Navarro-Esteva, F León-Marrero… - Open Respiratory …, 2020 - Elsevier